News

Filter

Current filters:

tivozanib

1 to 9 of 10 results

AVEO and Astellas finally terminate tivozanib collaboration

14-02-2014

US biotech firm AVEO Oncology and Japanese drug major Astellas Pharma are to end their worldwide collaboration…

Astellas PharmaAVEO OncologyBiotechnologyLicensingOncologytivozanib

AVEO Oncology restructuring and job cuts as tivozanib future in RCC in doubt

05-06-2013

Following a recent negative opinion on its lead product candidate from a Food and Drug Administration…

Astellas PharmaAVEO OncologyBiotechnologyFinancialManagementOncologyResearchtivozanib

FDA advisory votes against AVEO and Astellas' cancer drug tivozanib

03-05-2013

US biotech firm AVEO Oncology (Nasdaq: AVEO) saw its shares plunge as much as 57% in late trading yesterday…

Astellas PharmaAVEO OncologyBiotechnologyNorth AmericaOncologyPharmaceuticalRegulationtivozanib

AVEO/Astellas' kidney cancer drug tivozanib fails to beat Nexavar

14-02-2013

US biotech AVEO Oncology (Nasdaq: AVEO) and Japanese drug major Astellas Pharma (TYO: 4503) have announced…

Astellas PharmaAVEO OncologyBayerBiotechnologyNexavarOncologyOnyx PharmaceuticalsPharmaceuticalResearchtivozanib

AVEO and Astellas file NDA for tivozanib in kidney cancer

02-10-2012

USA-based AVEO Oncology (Nasdaq: AVEO) and Japanese drug major Astellas Pharma (TSE:4503) have submitted…

Astellas PharmaAVEO OncologyBiotechnologyNephrology and HepatologyNorth AmericaOncologyPharmaceuticalRegulationtivozanib

1 to 9 of 10 results

COMPANY SPOTLIGHT

Menarini

Back to top